DT2216
CAS No. 2365172-42-3
DT2216 ( —— )
产品货号. M24077 CAS No. 2365172-42-3
DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥8467 | 有现货 |
|
10MG | ¥13971 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称DT2216
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).
-
产品描述DT2216 inhibits various Bcl-XL-dependent leukemias and cancer cells, but is significantly less toxic to platelets.DT2216 is a selective B-cell lymphoma, extremely large (BCL-XL), proteolytic targeting chimera (PROTAC).DT2216 targets bcl-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation.
-
同义词——
-
通路Apoptosis
-
靶点Apoptosis
-
受体Apoptosis;PROTAC;VHL
-
研究领域——
-
适应症——
化学信息
-
CAS Number2365172-42-3
-
分子量1542.4
-
分子式C77H96ClF3N10O10S4
-
纯度>98% (HPLC)
-
溶解度H2O : < 0.1 mg/mL (insoluble); DMSO : 25 mg/mL (16.21 mM; Need ultrasonic)
-
SMILESCC1(C)CCC(C2=CC=C(Cl)C=C2)=C(C1)CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(S(C(F)(F)F)(=O)=O)=C(N[C@@H](CSC6=CC=CC=C6)CCN7CCN(C(CCCCCC(N[C@@H](C(C)(C)C)C(N8[C@@H](C[C@@H](O)C8)C(N[C@H](C9=CC=C(C%10=C(N=CS%10)C)C=C9)C)=O)=O)=O)=O)CC7)C=C5)=O)=O)C=C4)CC3
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.
产品手册
关联产品
-
Protein kinase inhib...
Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
-
SW-106065
SW-106065 is a novel pharmacologic inducer of apoptosis in MPNST (malignant peripheral nerve sheath tumors).
-
FR054 (b)
FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.